ADAM17 is not only required for development, but also triggers a number of distinct 151 pathways involved in various pathologies (reviewed in (158)). Accumulating data point 152 towards a critical function of this protease in acute lung inflammation. 153 ADAM17 was first discovered as the TNF cleaving enzyme, and initially this was thought to 154 be the predominant function of ADAM17 directly linking it to inflammatory diseases (11; 155 125). The importance of TNF in rheumatoid arthritis and inflammatory bowel disease but also 156 in acute respiratory distress syndrome (ARDS), asthma and severe COPD has long been 157 recognized (7). The significance of ADAM17 in humans is underlined by the fact that loss of 158 function mutations of ADAM17 are extremely rare; only one case has been found. The 159 peripheral blood leukocytes from this patient showed impaired release of TNF and the patient 160 suffered from repeated inflammatory skin and bowel diseases (12). Besides TNF, to date more 161 than 77 substrates for ADAM17 are known (reviewed in (163)). Importantly, growth factors 162 of the epidermal growth factor (EGF) family including transforming growth factor (TGF)α, 163 heparin-binding (HB)-EGF, amphiregulin, epiregulin and neuregulin (13; 161) are subject to 164 cleavage by ADAM17. Once released the growth factors can bind to receptors of the ErbB-165 family including ErbB1 (also termed epidermal growth factor receptor, EGFR), ErbB3 and 166
ErbB4 in a paracrine and autocrine fashion. This pathway is termed transactivation and provides 167 critical transcriptional signals to regulate proliferation and differentiation. Transactivation via 168 growth factor shedding is indispensable in developmental processes, but accumulating 169 evidence also suggests essential roles in tumor development and inflammation. The mere fact 170 that ErbB/EGFR signaling is involved in several inflammatory lung disorders including acute 171 lung inflammation, asthma and fibrosis (193) , together with the fact that ADAM17 is the 172 shedding protease for ErbB-family ligands, already suggests that this protease plays a crucial 173 role in pulmonary inflammation. As discussed below, beyond TNF and ErbB family ligands 174 there exist many other substrates by which ADAM17 can regulate inflammatory events in the 175 lungs: e.g. TNF receptors, IL6 receptor (IL6R), the tyrosine kinase Mer, L-selectin, the 176 transmembrane chemokine CX3CL1, the vascular cell adhesion molecule VCAM-1, the 177 intracellular cell adhesion molecule ICAM-1, the junctional adhesion molecule JAM-A, the 178 proteoglycan CD44 and chemokine-presenting syndecans and c-Kit (Table 1, Table 2 ). 204
205

Endothelial ADAM17 -a regulator of vascular responses in acute lung injury 206
Acute lung inflammation is characterized by an increased permeability of the pulmonary vascular 207 endothelium. Several properties of the endothelium that regulate vascular permeability such as 208 leukocyte adhesion, paracellular contact between endothelial cells and leukocyte transmigration 209 are regulated by ADM17, as indicated by studies with endothelial-specific knockout mice. 210
Mice with preferential ADAM17 deficiency in endothelial cells (driven by Tie2-Cre) have been 211 generated by several groups. In the first report no obvious vascular phenotype, but decreased 212 pathological neovascularization was observed in a cornea pocket assay (206) . Two other studies 213 described decreased collateral vessel formation (103) and defective remodeling of the semilunar 214 valves and cardiac dysfunction (208) . It is thought that the endothelial effects of ADAM17 215
Smooth muscle ADAM17 -a relay in acute lung inflammation 249
Pulmonary smooth muscle cells have long been suspected to play a role in inflammatory lung 250 diseases as these cells can produce relevant amounts pro-inflammatory mediators in vitro 251 (209). The possibility of generating smooth muscle-specific knockout mice now allows to 252 address this topic in a pathophysiological context. 253
Knockout of ADAM17 in smooth muscle cells (SMC) (driven by Tagln-Cre) does not display 254 any obvious physiological phenotype (206) . In the inflamed lung, smooth muscle cells may 255 hold a specialized function by transmitting inflammatory signals from and to the endothelial 256 cell layer. This concept is supported by in vivo and in vitro experiments on the role of 257 ADAM17 for inflammatory mediator production by SMC. Mice lacking ADAM17 in SMC 258 (driven by Tagln-Cre) showed considerably decreased lung damage, edema formation, 259 neutrophil recruitment, and cytokine production in response to intranasal LPS challenge (33). 260
Moreover, these mice were also protected in a model of acid-induced lung inflammation. Epithelial ADAM17 has been best characterized with respect to its role in lung development. 280
Lung epithelial knockout (driven by SPC-rTA/TetO-Cre) results in developmental defects 281 including reduced saccular formation and decreased proliferation and differentiation of mid-distal 282 epithelium (211). In cultured fetal epithelial cells mechanical strain was found to induce 283 ADAM17 activity via its binding to α 6 β 1 integrin leading to enhanced HB-EGF shedding and 284 differentiation (199) . In vitro findings on the transactivation of ErbB receptors via growth factor 285 shedding suggests a number of potentially pro-inflammatory properties of ADAM17 that 286 remain to be studied in more detail. (220) . It remains to be clarified to which extent 367 IL6R shedding by leukocyte ADAM17 occurs in the lung. In LPS-induced lung inflammation 368 ADAM17 deficiency had almost no effect on alveolar IL6R release (6; 146) which may be 369 explained by the fact that IL6R can also be shed by ADAM10, especially in mice (46). 370
In yet another pathway, ADAM17 mediates shedding of the receptor tyrosine kinase Mer on 371 phagocytic cells (184). Inhibition of Mer shedding enhances protective anti-inflammatory 372 functions of Mer in acute lung inflammation and this can be subverted by neutralization of 373 surface expressed Mer (23). These data suggest that ADAM17 can also abrogate protective 374 anti-inflammatory pathways by removal of surface expressed Mer. 375 376
Tissue inhibitor of metalloproteinases -endogenous ADAM17 inhibitor 377
Physiological homeostasis is characterized by a system of checks and balances. This is also 378 true for some ADAMs, although clearly this system has not been understood in full. The 379 tissue inhibitor of metalloproteinases (TIMP3) is an endogenous inhibitor that blocks some 380
MMPs and also ADAM17 (reviewed in (81)). In various mouse strains increased sensitivity 381 towards early bleomycin-induced fibrosis was correlated with lower TIMP3 expression and 382 higher ADAM17 activity (143). TIMP3 deficiency has a negative impact on lung structure 383 and function in response to sepsis (112). Further, TIMP3 deficiency prolongs bleomycin-384 induced lung inflammation with alveolar neutrophilia and prevents resolution of inflammation 385 (53). In LPS-induced lung inflammation, lack of TIMP-3 was associated with increased 386 macrophage polarization into the inflammatory M1 phenotype (52). Although TIMP3 seems 387 to attenuate pro-inflammatory events in the lung, it is not clear to which extent this is 388 mediated by the inhibition of ADAM17 or other metalloproteinases. 389 390 vivo by the use of knockout mice with cell specific ADAM10 deficiency (Table 3) 
ADAM 8 514
The contribution of ADAM8 towards allergic airway inflammation is still under discussion 515 that is founded on the adhesive and protease functions of ADAM8 related to cell migration. 516
The disintegrin domain of ADAM8 binds to α 9 β 1 integrin in an RGD-independent manner 517 (151), the relevance of which -except for osteoclast cell-to-cell interactions -remains to be 518 clarified. For ADAM8 only a few substrates have yet been reported. The protease can remove 519 the prodomain from pro-ADAM8 leading to its own activation (164). Recombinant ADAM8 520 is capable of cleaving peptides corresponding to the membrane proximal domains of TNF, 521 CX3CL1, stem cell factor (SCF), TNFR and TGFα (132). However, it is not clear whether 522
ADAM8 is a sheddase for the full-length molecules on the cell surface, especially in vivo. 
Inhibition of ADAMs in acute lung inflammation 662
There is increasing evidence that treatment with exogenous synthetic metalloproteinase 663 inhibitors can limit hallmarks of acute pulmonary inflammation (Table 5) . Since these 664 inhibitors were mostly broad spectrum inhibitors and were delivered systemically, their 665 effects are most likely explained by the inhibition of distinct metalloproteinase activities on 666 multiple cell types. As described above, ADAM10 and ADAM17 fulfill multiple roles in 667 various cell types. For example, ADAM17 on endothelial cells and SMC acts pro-668 inflammatory in a murine model of acute pulmonary inflammation (32), whereas leukocytic 669 ADAM17 seems to play a negligible role in acute lung inflammation (146) 
Open questions -potential roles of ADAMs in chronic inflammation and infectious diseases 721 of the lung 722
In addition to the overall pro-inflammatory role of ADAM10 and ADAM17 in the early phase 723 of acute lung inflammation, both proteases may also critically regulate chronic inflammation. 
